We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
CTI BioPharma announced the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The company expects to report the determination of ......